Skip to content Skip to sidebar Skip to footer

Newsletter

Growth Stocks

Does The Nuix Judgement Mean All the Company’s Trouble Are Over?

2026 has 8 months to go, but we think that the Nuix Judgement (i.e. the Federal Court’s dismissal of ASIC’s case against Nuix) will be the most consequential corporate law outcome of the year. The impact goes beyond Nuix and could well influence ASIC's boldness to pursue corporate cases. The judgement clarified that forecasts must be…

ByNick SundichApril 24, 2026

Black Cat Syndicate (ASX:BC8): From Funded Developer to Multi-Asset Gold Producer — What’s Next?

When we last wrote about Black Cat Syndicate (ASX:BC8) in December 2023, the company had just secured a A$60m equity investment from Chinese industry investors — a pivotal moment for a developer that had spent years assembling a multi-asset gold portfolio in Western Australia. Since then, BC8 has graduated from developer to producer, achieved first…

ByNick SundichApril 22, 2026

Dimerix And Its DMX-200 (Qytovra) Therapy Approach Their Most Important Catalyst

After several years of advancing DMX-200/Qytovra, Dimerix is entering the most consequential chapter of its life. The upcoming blinded statistical powering analysis for ACTION3 is the moment where all of that groundwork will likely pay off. Dimerix has been advancing DMX-200/Qytovra for several years DMX-200 is a targeted anti‑inflammatory therapy designed to block the CCR2 pathway…

ByNick SundichApril 21, 2026

How To Read a Balance Sheet As An Investor: The 7 Questions Prudent Investors Need to Ask!

Knowing how to read a balance sheet is a key skill investors need to know, because the balance sheet is the most underrated document in an annual report. Most new investors skip straight to earnings - perhaps not knowing how importance the balance sheet is or having an appreciate but not knowing how to read…

ByNick SundichApril 21, 2026

Omni Bridgeway (ASX:OBL): Up 20% This Year Off The Back of Litigation Financing!

Omni Bridgeway (ASX:OBL) occupies one of the most unusual niches in global capital markets. It is not a law firm, nor a traditional investment manager, nor a credit provider in the conventional sense. Instead, it sits at the intersection of legal process, capital allocation, and risk underwriting. The company funds litigation and arbitration claims in…

ByNick SundichApril 20, 2026

These 8 ASX Growth Stocks Have High P/Es

If you're looking at ASX Growth Stocks with high P/Es you have two choices. First, you could write certain companies off just because of high multiples, only to lose out when such companies continue to grow. Alternatively, you could jump in and risk the company falling and be left red faced - 'If only I'd…

ByNick SundichApril 17, 2026

The Iran Ceasefire Rally Is On! But Investors Aren’t Responding In the Right Way

Add a new term to your vocabulary: The Iran Ceasefire Rally. The rally on the ASX yesterday, that saw our bourse rise over 2.5% in its best day in several months, occurred amidst a 2 week suspension of hostilities in Iran. And the ASX was not alone with Asian markets and North American futures rallying,…

ByNick SundichApril 9, 2026

Kingsgate Consolidated (ASX:KCN): This ASX 300 Gold And Silver Stock Quadrupled Last Year!

Kingsgate Consolidated (ASX: KCN) delivered a 344% share price gain in CY25, representing the second‑strongest performance among ASX All Ordinaries stocks with a focus on gold. Returns of that magnitude usually generate two reactions: satisfaction from those who held the stock, and the assumption from others that the opportunity has already passed. The current environment…

ByNick SundichApril 9, 2026

The Latest Guzman y Gomez Trading Update Was Well Received! But Have Things Really Changed?

Almost every Guzman y Gomez trading update since it listed has resulted in volatile share price movements one way or the other. And today was no exception. But only weeks after falling 14% off the back of 1H26 results, today's Q3 sales figures sent shares up 20% in early trade. What's the story here? Have…

ByNick SundichApril 7, 2026

ASX Biotech Investing In 2026: Investors Are More Aware Of The Hard Lessons, But Have Forgotten The Hidden Rewards Of It

ASX Biotech Investing has always been the market’s most difficult arena. Yes tech and resources are risky spaces too, but at least a gold explorer can gain just off the back of gold price momentum or activity from neighbouring peers. With biotech it is all on the success of the individual company. The science is extraordinary…

ByNick SundichApril 7, 2026

the Kick-ass Multipurpose WordPress Theme

Growth Stocks

Does The Nuix Judgement Mean All the Company’s Trouble Are Over?

Black Cat Syndicate (ASX:BC8): From Funded Developer to Multi-Asset Gold Producer — What’s Next?

Dimerix And Its DMX-200 (Qytovra) Therapy Approach Their Most Important Catalyst

How To Read a Balance Sheet As An Investor: The 7 Questions Prudent Investors Need to Ask!

Omni Bridgeway (ASX:OBL): Up 20% This Year Off The Back of Litigation Financing!

These 8 ASX Growth Stocks Have High P/Es

The Iran Ceasefire Rally Is On! But Investors Aren’t Responding In the Right Way

Kingsgate Consolidated (ASX:KCN): This ASX 300 Gold And Silver Stock Quadrupled Last Year!

The Latest Guzman y Gomez Trading Update Was Well Received! But Have Things Really Changed?

ASX Biotech Investing In 2026: Investors Are More Aware Of The Hard Lessons, But Have Forgotten The Hidden Rewards Of It

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Growth Stocks

Stocks in Spotlight

Add Your Heading Text Here